US Patent

US10117844 — DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form

Method of Use · Assigned to Chrysalis Pharma AG · Expires 2033-01-04 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form and methods for their use.

USPTO Abstract

DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.

Drugs covered by this patent

Epanova (OMEGA-3-CARBOXYLIC ACIDS) · AstraZeneca

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2447`	—	Epanova

Patent Metadata

Patent number: US10117844
Jurisdiction: US
Classification: Method of Use
Expires: 2033-01-04
Drug substance claim: No
Drug product claim: No
Assignee: Chrysalis Pharma AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.